Biomarkers

Name
Biomarkers
Accession Number
DBCAT000037
Description

Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc.

Drugs
Drug Drug Description
L-Pentahomoserine Not Available
O-(N-acetyl-alpha-D-galactosaminyl)-L-serine Not Available
Human blood group H type 1 trisaccharide Not Available
Nelipepimut-S Investigated for use/treatment in prostate cancer and breast cancer.
Eftilagimod alfa Eftilagimod alfa is under investigation in clinical trial NCT02614833 (IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma).
Reltecimod Reltecimod is under investigation in clinical trial NCT02469857 (Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections).
Drugs & Drug Targets
Drug Target Type
Human blood group H type 1 trisaccharide Histo-blood group ABO system transferase target
Nelipepimut-S HLA class I histocompatibility antigen, A-2 alpha chain target
Nelipepimut-S HLA class I histocompatibility antigen, A-3 alpha chain target